Yahoo Web Search

Search results

1. • Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop...

     Fontana Herald News· 17 hours ago

     Poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.

2. • Small Business - Cordele Dispatch | Cordele Dispatch

     Cordele Dispatch· 1 day ago

     Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will ...

3. • Taysha Gene Therapies Inc (TSHA) receives an Overweight rating from Piper Sandler – Knox Daily

     Knox Daily· 3 days ago

     As a result of the transaction, Manning Paul B now holds 16,466,667 shares, worth roughly $39.36 million. Piper Sandler initiated its Taysha Gene Therapies Inc [TSHA] rating ...

4. • Think You Need A Good Stock? Look At This Taysha Gene Therapies Inc

     Stocks Register· 1 day ago

     The beta value is 0.32, while the average true range (ATR) is currently pointing at 0.25. Coming back to Taysha Gene Therapies Inc (NASDAQ:TSHA), we note

5. • 

     Gene Therapy Trial for Sickle Cell Disease Publishes Final Results

     Technology Networks· 7 days ago

     In a landmark study, an international consortium led by researchers at Children’s Hospital of...

6. • 

     Moderna (MRNA) Q1 2024 Earnings Call Transcript

     Motley Fool via Yahoo Finance· 2 hours ago

     We also made public our collaboration with OpenAI to use AI as a transformative tool to increase speed and efficiency, and ultimately to improve patient...

7. • 

     FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

     Benzinga via Yahoo Finance· 6 days ago

     Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate...

8. • 

     Earnings call: Avid Bioservices sees revenue boost, optimistic on growth

     Investing.com· 3 days ago

     Despite this quarterly rise, the company observed a decrease in revenues compared to the same...

9. • Q3 2024 Earnings Forecast for Sarepta Therapeutics, Inc. Issued By Zacks Research (NASDAQ:SRPT)

     ETF DAILY NEWS· 16 hours ago

     (NASDAQ:SRPT – Free Report) – Equities research analysts at Zacks Research upped their Q3 2024 EPS estimates for Sarepta Therapeutics in a research note issued on Monday, ...

10. • 

      Earnings call: Avid Bioservices sees revenue boost, optimistic on growth By Investing.com

      Investing.com· 2 days ago

      Despite this quarterly rise, the company observed a decrease in revenues compared to the same...